Evaluation of HPV Genotyping as Diagnostic Biomarkers of Cervical Cancer Risk – On Applications of HPV Genotyping Detection

HPV infection is frequent in sexually active people, but the persistent infection develops only in a small proportion of cases. HPV persistence involves a risk of developing precancerous cervix lesions and, eventually, cervical cancer

HPVs cannot be cultured in vitro by conventional methods, and the wide natural variation of the humoral immune response after the infection impairs the use of HPV-specific antibody testing in diagnosis. Diagnosis of the HPV infection is, therefore, achieved by molecular testing, mainly by detection of genomic HPV DNA.

Currently, a wide variety of commercial HPV genotyping methods exist. Selection of the more appropriate one depends on the intended use, i.e.: epidemiology, vaccine evaluation, or clinical studies.

For epidemiological studies, HPV genotyping methods allow drawing of type specific prevalence.
For vaccine evaluation, these assays provide data in regard to changes in prevalence for HPV types not included in the current vaccines, and facilitate the follow up of persistent infections
For clinical studies, the current international guidelines recommend the use of HPV genotyping tests among women 30 years and older with negative cytology and a HR HPV positive results, in special HPV-16 and HPV-18. Detecting HPV and discriminating high- and low-risk genotypes twice or more  to find patients with  the same genotype persistent infections, resulting in better clinical management. 

Macro & Micro-Test HPV genotyping kits:

• 14 HPV Types (Genotyping) Nucleic Acid Detection Kit (Fluorescence PCR)
• Freeze-dried 14 HPV Types (Genotyping) Nucleic Acid Detection Kit(Fluorescence PCR)  
• 28 HPV Types (Genotyping) Detection Kit (Fluorescence PCR)(18 HR-HPVs +10 LR-HPVs)
• Freeze-dried 28 HPV Types( Genotyping) Detection Kit (Fluorescence PCR)

Key product features:

• Simultaneous detection of multiple genotypes in one reaction;
• Short PCR turnaround time for quick clinical decisions;
• More sample types (urine/swab) for more comfortable and accessible HPV infection screening;
• Dual Internal Controls prevents false positives and validates test reliability;
• Liquid and lyophilized versions for clients' options;
• Compatibility with most PCR systems for more lab adaptability.